Early signs of interstitial lung disease, including IPF, can be common things like a cough or reflux. A pulmonologist explains what else to look for and when to see a doctor.

Preclinical data indicate that inhaled treprostinil may be useful for the treatment of idiopathic pulmonary fibrosis (IPF) through an antifibrotic mechanism, a premise that is supported by clinical ...

Idiopathic pulmonary fibrosis, a rare progressive disease characterized by fibrosis in the alveoli of the lungs, has a median survival of 3 to 5 years if left untreated. Inhaled treprostinil slowed ...

CHICAGO, March 5, 2026 /PRNewswire/ -- The Pulmonary Fibrosis Foundation's Care Center Network has grown to include 96 sites in 40 states as part of its first expansion since 2023, marking a milestone ...

Because evidence gaps in idiopathic pulmonary fibrosis research hinder demonstration of antifibrotic therapies’ impact on patient quality of life (QOL), integrating validated health-related QOL ...

Fatigue can have a significant impact on quality of life, and it generally stems from several factors including difficulty breathing, disrupted sleep, anxiety and depression, and medications used to ...

Environmental factors including temperature, humidity, air quality, and seasonal changes can significantly impact idiopathic pulmonary fibrosis (IPF). These triggers can exacerbate symptoms and lead ...

What Is Jascayd, and Why Does It Matter? Jascayd (nerandomilast) is now approved for treating adults with progressive pulmonary fibrosis (PPF) that causes gradual and permanent scarring in the lungs, ...

Please provide your email address to receive an email when new articles are posted on . Nerandomilast is the first oral preferential phosphodiesterase 4B inhibitor approved for progressive pulmonary ...

Idiopathic pulmonary fibrosis (IPF) is a chronic disease in which healthy lung tissue is gradually replaced by scar tissue. While the early events that initiate this change are poorly understood, ...

Please provide your email address to receive an email when new articles are posted on . The FDA based nerandomilast’s approval on results from two trials, one of which was the FIBRONEER-IPF trial.

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...